Royal Holloway seeks to ensure that the outputs of its research and new knowledge make their potential impact in a timely manner. Knowledge transfer through commercialisation would usually take the form of the licensing of a patent or copyright or the formation of a spin out company which can then seek investment to develop the technology further or the provision of consultancy services, etc.
We are mindful of the fact that the introduction of new technology and the adoption of new ideas carries risk. To encourage innovation and to reflect our mission for timely and effective knowledge transfer, our licensing terms are designed to be attractive to business and we work closely with our commercial partners to maximise the potential for early success.
The current licensing opportunities page provides a list of some of current technologies which we think have potential for commercialisation.
Royal Holloway will support the formation of a spin out company in circumstances where external investment is needed to develop the research to commercial viability. We are also able to provide spin out companies with access to our incubation facilities.
The following case studies demonstrate the range and nature of knowledge transfer activity at Royal Holloway. For more information or to discuss how your business might benefit from working with Royal Holloway, please contact the Head of Research and Business Development.
Parity Group Plc and Royal Holloway,University of London have announced they are working together to implement an innovative social media search tool. Developed by researchers needing to recognise links and associations within massive data sets, the new software, GroupSeer™ offers the potential to better understand the behaviour of on-line users based on insights into human social behaviour. The patented algorithm uses a powerful and unique combination of social graph and language techniques.
SporeGen is a spin-out from Royal Holloway focussing on Bacillus and its commercial applications in novel vaccine technologies, probiotics, drug delivery and targeting and related sectors. Founded in 2012 by Prof Simon Cutting, SporeGen is, amongst other products, developing heat-stable vaccines that can be delivered needle-free either orally or nasally. The company is currently developing two lead vaccine candidates and has partners in Europe, India and Vietnam. Go to SporeGen's website for more information.
MVE has worked with the Department of Earth Sciences at Royal Holloway to develop software which predicts the distribution and capacity of oil within single wells. As a result of the collaboration, MVE has an exclusive licence to use the software within their organisation and to re-sell to other users.